A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication: Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer
Trial Number: 06496178
Trial Status: OPEN